Evotec SE: translational BRIDGE partnership beLAB2122 selects oncology project from Goethe University Frankfurt

GOAL IS TO DEVELOP A BIFUNCTIONAL DEGRADER TO INTERFERE WITH THE RNA SPLICING TO DEVELOP A FIRST-IN-CLASS CANCER TREATMENT


PROJECT ORIGINATES... | July 5, 2022

Related Keywords

Germany ,Frankfurt Am Main ,Hessen ,Hamburg ,Frankfurt ,Brandenburg ,Thomas Hanke ,Institute For Biochemistry ,University Of Frankfurt ,Goethe University ,Bristol Myers Squibb ,Evotec Se Frankfurt Stock Exchange ,Goethe University Frankfurt ,Nasdaq ,Frankfurt Stock Exchange ,Bristol Myers ,Academic Partnerships ,Evotec Se Stock Exchange ,News ,Information ,Press Release ,Goal ,Us ,O ,Evelop ,Bifunctional ,Egrader ,Interfere ,Ith ,The ,Na ,Splicing ,Dancer ,Treatment ,Roject Evt De0005664809 ,